|
시장보고서
상품코드
2017940
비대성 심근병증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 질환 유형별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)Hypertrophic Cardiomyopathy Therapeutics Market Size, Share & Trends Analysis Report By Drug Class,, By Disease Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
비대성 심근증 치료제 시장 요약
세계의 비대성 심근병증 치료제 시장 규모는 2025년에 14억 3,000만 달러로 추정되며, 2033년까지 21억 6,000만 달러에 달할 것으로 예측됩니다.
2026년부터 2033년까지 CAGR 5.5%로 성장할 것으로 예상됩니다. 이 산업은 질병의 근본적인 메커니즘에 작용하는 표적 약물 치료의 채택이 증가함에 따라 확대되고 있습니다.
심근 미오신 억제제의 도입으로 치료 전략은 증상 조절에서 질병 변형으로 전환되어 장기적인 임상 관리가 가능해졌습니다. 첨단 영상 진단 기술과 유전자 검사로 인한 진단율의 상승은 모든 연령층에서 식별 가능한 환자군을 확대하고 있습니다. 순환기 전문의들 사이에서 임상적 인식이 높아짐에 따라 조기 개입이 촉진되고 있습니다. 예를 들어, 2025년 1월 가디언지는 500명 중 1명이 앓고 있는 비후성 심근증에 대해 50년 동안 일률적으로 15mm의 심벽 두께 기준치가 사용되어 왔기 때문에 여성의 진단이 과소평가되어 왔다고 보도한 바 있습니다. 이 질환의 발병률은 남녀가 비슷하지만, 진단받은 환자의 3분의 2는 남성이었습니다. 1,600명의 환자를 대상으로 한 연구에서 여성 식별률이 20% 포인트 향상되었고, 43,000명 이상을 대상으로 한 분석에서는 개별화된 기준에 따라 여성이 44%를 차지하는 것으로 나타났습니다. 모니터링의 개선과 전문 의료기관 네트워크의 확대는 세계 시장의 지속적인 성장을 더욱 촉진하고 있습니다.
또 다른 주요 성장 요인은 심혈관 치료제 파이프라인의 임상 연구와 제품 혁신의 지속적인 진전입니다. 제약사들은 효능과 안전성 프로파일을 개선하기 위해 차세대 살코메어 조절제, 새로운 저분자 화합물 및 정밀 의학에 대한 접근 방식에 투자하고 있습니다. 예를 들어, 2026년 2월 엘제비아는 ScienceDirect에서 '비대성 심근증에서 마바카멘텐과 아피카멘텐'을 발표하며, 비대성 심근증은 좌심실 비대 및 심근세포의 배열 이상에 의해 정의된다고 밝혔습니다. 본 논문에서는 마바캄텐과 아피캄텐이 단순히 증상 완화뿐만 아니라 질병의 진행 자체를 변화시키는 역할을 검증하고, 폐색형 및 비폐색형 표현형을 가진 성인을 대상으로 수천 명의 피험자를 대상으로 한 2상 및 3상 임상시험에 대해 논의했습니다. 또한, 위약 대비 좌심실 유출로 압력 차이 감소, 운동 능력 및 삶의 질 개선이 확인되었다는 점을 인용하며, 치료 방침의 전환을 뒷받침하는 수치적 평가지표를 강조했습니다. 임상적 효능이 확대되고 규제 당국의 승인이 진행됨에 따라 주요 의약품 시장에서 상업적 보급이 계속 가속화되고 있습니다.
이 시장은 심혈관질환의 부담 증가와 전 세계 고령화 사회에서 유전성 심근증에 대한 인식이 높아짐에 따라 더욱 활성화되고 있습니다. 고혈압, 대사성 질환을 포함한 생활습관 관련 위험인자가 심장 검사의 빈도 증가와 비후성 심근증의 우발적 진단에 기여하고 있습니다. 예를 들어, 2024년 7월 메디콤 메디컬 퍼블리셔스는 폐색성 비대성 심근증에 대한 아피캄텐의 효능을 평가하는 3상 SEQUOIA-HCM 임상 3상 시험을 보고한 바 있습니다. 본 임상시험에는 282명의 피험자가 등록되어 아피캄텐+표준치료군과 위약군에 1:1의 비율로 무작위 배정되었습니다. 대상자 선정 기준은 좌심실 유출로 압력 차이가 30mmHg 이상, 발살바 압력 50mmHg 이상, 뉴욕심장협회(NYHA) 분류 II 또는 III 증상, 연령 및 성별에 따른 예측 최대 산소섭취량이 90% 이하인 경우로 설정했습니다. 24주 시점에서 최대 산소 섭취량은 대조군의 0.0 mL/kg/min 대비 1.74 mL/kg/min(95% 신뢰구간 1.0-2.4, P=0.000002)의 최소 제곱 평균 차이로 1.74 mL/kg/min(95% 신뢰구간 1.0-2.4, P=0.000002)로 나타나, 전 세계적으로 치료 도입의 지속성을 입증했습니다. 입증되었습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 비대성 심근병증 치료제 시장 : 변수, 동향, 범위
제4장 비대성 심근병증 치료제 시장 : 약물 종류별 비즈니스 분석
제5장 비대성 심근병증 치료제 시장 : 질환 유형별 비즈니스 분석
제6장 비대성 심근병증 치료제 시장 : 투여 경로별 비즈니스 분석
제7장 비대성 심근병증 치료제 시장 : 유통 채널별 비즈니스 분석
제8장 비대성 심근병증 치료제 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSM 26.05.12Hypertrophic Cardiomyopathy Therapeutics Market Summary
The global hypertrophic cardiomyopathy therapeutics market size was estimated at USD 1.43 billion in 2025 and is projected to reach USD 2.16 billion by 2033, growing at a CAGR of 5.5% from 2026 to 2033. The industry is expanding due to the increasing adoption of targeted pharmacological therapies that address underlying disease mechanisms.
The introduction of cardiac myosin inhibitors has shifted treatment strategies toward disease modification rather than symptom control, supporting long-term clinical management. Rising diagnosis rates driven by advanced imaging technologies and genetic testing have broadened the pool of identifiable patients across age groups. Greater clinical awareness among cardiologists has encouraged earlier intervention. For instance, in January 2025, The Guardian reported that hypertrophic cardiomyopathy, affecting one in 500 people, had been underdiagnosed in women due to a uniform 15 mm wall thickness threshold used for 50 years. Two in three diagnosed patients were men, although women were equally likely to have the condition. A study of 1,600 patients improved female identification by 20 percentage points, and analysis of over 43,000 individuals showed women represented 44 percent under personalized criteria. Improved monitoring and specialty distribution networks further support sustained market growth globally.
Another major growth driver is the continuous advancement of clinical research and product innovation within the cardiovascular therapeutics pipeline. Pharmaceutical companies are investing in next-generation sarcomere modulators, novel small molecules, and precision medicine approaches designed to improve efficacy and safety profiles. For instance, in February 2026, Elsevier published "Mavacamten and Aficamten in Hypertrophic Cardiomyopathy" on ScienceDirect, stating that hypertrophic cardiomyopathy was defined by left ventricular hypertrophy and myocyte disarray. The article reviewed the roles of mavacamten and aficamten in modifying disease processes rather than only addressing symptoms, and discussed phase 2 and phase 3 studies involving adults with obstructive and nonobstructive phenotypes with sample sizes in the thousands. It referenced reductions in left ventricular outflow tract gradients and improvements in exercise capacity and quality of life compared with placebo benchmarks, highlighting numerical endpoints that supported therapeutic shifts. Expanding clinical validation and regulatory progress continue to accelerate commercial uptake across major pharmaceutical markets.
The market is further supported by the growing burden of cardiovascular disorders and increased recognition of genetic cardiomyopathies in aging populations worldwide. Lifestyle related risk factors, including hypertension and metabolic conditions, have contributed to more frequent cardiac assessments and incidental diagnosis of hypertrophic cardiomyopathy. For instance, in July 2024, Medicom Medical Publishers reported on the phase 3 SEQUOIA-HCM trial evaluating aficamten in obstructive hypertrophic cardiomyopathy. The study enrolled 282 participants randomized 1:1 to aficamten plus standard of care or placebo. Eligibility criteria included a left ventricular outflow tract gradient >=30 mmHg and Valsalva >=50 mmHg, New York Heart Association class II or III symptoms, and predicted peak oxygen uptake <=90% for age and sex. At week 24, peak oxygen uptake improved by +1.8 mL/kg/min versus 0.0 mL/kg/min, with a least-squares mean difference of 1.74 mL/kg/min, 95% CI 1.0 to 2.4, P=0.000002, supporting sustained therapeutic adoption globally.
Global Hypertrophic Cardiomyopathy Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hypertrophic cardiomyopathy therapeutics market report based on drug class, disease type, route of administration, distribution channel, and region:
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Beta Blockers
- Calcium Channel Blockers
- Antiarrhythmic Drugs
- Cardiac Myosin Inhibitors
- Anticoagulants
- Others
- Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Injectable / Parenteral
- Others
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Disease Type
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Hypertrophic Cardiomyopathy Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Hypertrophic Cardiomyopathy Therapeutics Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2025 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
- 4.4. Beta Blockers
- 4.4.1. Beta Blockers Market, 2021 - 2033 (USD Million)
- 4.5. Calcium Channel Blockers
- 4.5.1. Calcium Channel Blockers Market, 2021 - 2033 (USD Million)
- 4.6. Antiarrhythmic Drugs
- 4.6.1. Antiarrhythmic Drugs Market, 2021 - 2033 (USD Million)
- 4.7. Cardiac Myosin Inhibitors
- 4.7.1. Cardiac Myosin Inhibitors Market, 2021 - 2033 (USD Million)
- 4.8. Anticoagulants
- 4.8.1. Anticoagulants Market, 2021 - 2033 (USD Million)
- 4.9. Others
- 4.9.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Hypertrophic Cardiomyopathy Therapeutics Market: Disease Type Business Analysis
- 5.1. Disease Type Market Share, 2025 & 2033
- 5.2. Disease Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Disease type, 2021 to 2033 (USD Million)
- 5.4. Obstructive Hypertrophic Cardiomyopathy (oHCM)
- 5.4.1. Obstructive Hypertrophic Cardiomyopathy (oHCM) Market, 2021 - 2033 (USD Million)
- 5.5. Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- 5.5.1. Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Market, 2021 - 2033 (USD Million)
Chapter 6. Hypertrophic Cardiomyopathy Therapeutics Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
- 6.4. Oral
- 6.4.1. Oral Market, 2021 - 2033 (USD Million)
- 6.5. Injectable / Parenteral
- 6.5.1. Injectable / Parenteral Market, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Hypertrophic Cardiomyopathy Therapeutics Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
- 7.7. Specialty Pharmacies
- 7.7.1. Specialty Pharmacies Market, 2021 - 2033 (USD Million)
Chapter 8. Hypertrophic Cardiomyopathy Therapeutics Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Europe
- 8.5.1. Europe Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. Uk Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Hypertrophic Cardiomyopathy Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Bristol Myers Squibb
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Cytokinetics, Inc.
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Novartis AG
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Sanofi
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Bayer AG
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Tenaya Therapeutics
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Imbria Pharmaceuticals
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Rocket Pharmaceuticals
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Lexeo Therapeutics
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. Edgewise Therapeutics
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.1. Bristol Myers Squibb
